Temple B, et al. - Via this parallel, open-label, randomized controlled trial, a head-to-head comparison of the immunogenicity and reactogenicity of ten-valent pneumococcal conjugate vaccine (PCV10) and 13-valent pneumococcal conjugate vaccine (PCV13) was reported. Using a computer-generated list, researchers randomly allocated healthy infants from two districts in Ho Chi Minh City, Vietnam (in a 3:3:5:4:5:4 ratio) to one of six infant PCV schedules: PCV10 in a 3 + 1 (group A), 3 + 0 (group B), 2 + 1 (group C), or two-dose schedule (group D); PCV13 in a 2 + 1 schedule (group E); or no infant PCV (control; group F). Outcomes revealed similar high immunogenicity of PCV10 and PCV13 when used in 2 + 1 schedule. Factors such as the comparative magnitude of the antibody responses, price, and the relative importance of different serotypes in different settings were seemed to influence the choice of the vaccine.